Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

The anti-TNF era was followed by the emergence of interleukin (IL ... where she gained in-depth knowledge of drug discovery, development, and the pharmaceutical industry's strategic landscape ...

Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...

Alex Zhavoronkov, founder & CEO of Insilico Medicine, stated that he “firmly believes that the repurposing of FDA-approved drugs with demonstrated anti-ageing potential represents a highly ...

Aclaris Therapeutics Inc. has gained IND clearance from the FDA for ATI-052, a bispecific anti-thymic stromal lymphopoietin (TSLP)/interleukin-4 receptor (IL-4R) monoclonal antibody being developed to ...

Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater ...

According to a new study published on Thursday in the journal Science, young salmon exposed to anti-anxiety drugs in the water made it past dams faster. But ecologists are doubtful that it means a ...

Prescription anti-inflammatory medications are used to reduce pain, inflammation, and fever in acute and chronic medical conditions. They are also called nonsteroidal anti-inflammatory drugs (NSAIDs).

Anti-TNF biologics, methotrexate, and other older systemic medications showed rates between ... Researchers conclude that biologics targeting interleukin pathways may be safer alternatives for ...

Following the presentations, each poster will be available on Connect’s website under the Presentations and Publications section.

Get more information about the medications, ustekimumab ... giving PsA patients who haven’t responded to existing treatments another option. Unlike anti-TNFs, ustekinumab targets two other molecules ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly ...